Until recently, a one-size-fits-all approach for firefighter respiratory protection might have been considered the norm. However, no two fire stations are alike, and each has differing needs, preferences and expectations of their protective equipment. This understanding served as the key driver behind the development of a new and innovative self-contained breathing apparatus (SCBA) platform – called the M1 SCBA – that was unveiled today at the 125th French Firefighters Congress by MSA Safety Incorporated (NYSE: MSA), a global leader in firefighter safety.
To view the multimedia release go to:
Rowenta, maker of the revolutionary new air purifier the Intense Pure Air, is collaborating with renowned Environmental Toxicologist Dr. Noreen Khan-Mayberry (aka “The Tox Doc”), to help allergy sufferers better manage their symptoms. An estimated 50 million Americans are allergic to dust, dander, mold and mites, which can cause trouble breathing, excessive sneezing, eye irritation and coughing, amongst other ailments.
Seasonal allergies affect approximately 30% of U.S. residents and are worsening due to climate change, which is not only causing an increase in pollen levels, but also extending the length of pollen season. As such, allergy sufferers and people with asthma and other respiratory issues are at an even greater risk for heightened symptoms both indoors and outdoors.
To view the multimedia release go to:
With the onset of winter season in the country, breathing problems and respiratory diseases will also be on the rise. To ensure that patients with respiratory problems breathe with ease, a comprehensive patient Mobile App named “My Breathefree” has been launched as a virtual caregiver by ‘Breathefree’, a public service initiative by Cipla. This app is specifically designed for Indian conditions and is available on Google play store and iOS platform for all patients, caregivers and doctors.
One of the major chronic respiratory problems in the country is asthma and “My Breathefree” app will be a great help towards better asthma management and control. Asthma causes limitations in daily activities, loss of school and work days, lung function impairment, reduced quality of life and an adverse socioeconomic burden. However, if monitored and treated properly, asthmatics can control their disease and lead an absolutely normal and healthy life.
To view the multimedia release go to:
The Asthma and Allergy Foundation of America (AAFA) and Teva Respiratory announced today the launch of a national awareness campaign – Know Your Count – aimed at raising awareness of the seriousness of asthma and educating asthma patients and caregivers about the importance of keeping track of the remaining doses in their rescue inhalers. The campaign features award-winning singer and actress, Kristin Chenoweth, who is speaking publicly for the first time about the impact her asthma has had on her professional career and busy lifestyle. For more information about the Know Your Count campaign, Kristin’s experience with asthma and to view an important public service announcement (PSA), visit www.KnowYourCount.com.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/65058-teva-respiratory-aafa-know-your-count-managing-asthma/
The Asthma and Allergy Foundation of America (AAFA) and Teva Respiratory released results today from a new survey which showed that more than half (59 percent) of nasal allergy sufferers polled reported sleep issues as a result of their allergy symptoms, yet only 35 percent proactively treat their nasal allergy symptoms. Furthermore, nearly half of those surveyed (48 percent) said their nasal allergy symptoms, such as nasal congestion and sneezing, also interrupted their partner’s sleep.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60975-teva-respiratory-aafa-ditch-the-drip-misty-may-treanor-nasal-allergies
Crosstex International, a subsidiary of Cantel Medical Corp. (NYSE:CMN), and Prestige Ameritech, the only two major U.S.-based medical mask manufacturers have joined forces to bring attention to a glaring void in public health research and policy – that, if addressed, has the potential to more quickly provide a simple, effective tool to mitigate the spread of influenza and other respiratory borne viruses. The awareness campaign comes in response to a new study, “ Exposure to Influenza Virus Aerosols During Routine Patient Care,” published in The Journal of Infectious Diseases, showing that influenza viruses may spread as far as six feet from a person coughing or sneezing, and that some people, referred to as “super spreaders,” may be more likely to spread the virus. The study, supported by the Department of Health and Human Services with a $600,000 research grant, pointed specifically to concerns for healthcare workers being exposed to coughs from sick patients. Yet government research and policy continues to overlook face masks as a feasible protection measure for both the healthcare industry and the general public.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60417-cantel-medical-fitted-mask-infectious-disease-control-public-health-policy
Takeda today announced the launch of a new expert Report on COPD, introduced at a Takeda organised press conference on the occasion of the 2012 European Respiratory Society (ERS) Annual Congress taking place from 1- 5 September in Vienna, Austria.
The Report, entitled ‘The Shifting Paradigm in Chronic Obstructive Pulmonary Disease (COPD) Management,’ was initiated and developed by Takeda Pharmaceuticals International GmbH and is a compilation of opinion articles from a panel of key international respiratory experts, the European Federation of Allergy and Airways Diseases Patients’ Association (EFA) and COPD patients, reflecting updated guidance and research. The new expert Report was developed in response to a recent shift in emphasis in COPD management which now places future risk at equal importance to treatment of current disability. Treatment objectives are now divided into two groups: reducing symptoms and reducing risk.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56582-expert-report-on-copd-launch
Prilosec Side Effects : Headaches, Abdominal pain, Diarrhea, Upper
respiratory tract infections, Dizziness, Constipation, Back pain. Watch
this video for detail side effects of prilosec.
Teva Respiratory and the Asthma and Allergy Foundation of America (AAFA) announced today the launch of a national awareness campaign - Ditch the Drip, Get Serious about Nasal Allergies - aimed at raising awareness of the seriousness of seasonal and year-round allergies and the need for people living with nasal allergies to adequately prepare for their peak allergy seasons. The program features two-time Olympic volleyball gold medalist and seasonal allergy sufferer Misty May-Treanor. Misty is speaking up for the first time about the impact her nasal allergies have had on both her career and personal life, as she prepares to compete in the 2012 Summer Olympic Games in London. For more information on the Ditch the Drip program, Misty's experience with allergies and to view an important public service announcement (PSA), visit www.DitchtheDrip.com.
To view Multimedia News Release, go to http://www.multivu.com/players/English/54675-ditch-the-drip-get-serious-about-nasal-allergies/
Boston Scientific Corporation (NYSE: BSX) announces positive clinical data from the Research in Severe Asthma (RISA) Trial, demonstrating the long-term safety of bronchial thermoplasty (BT) in patients treated with the Company’s AlairTM Bronchial Thermoplasty System. Follow-up data demonstrate that stable lung function is maintained and late clinical complications are absent over a five-year period in patients with severe refractory asthma treated with BT. Results were presented today at the annual European Respiratory Society (ERS) Congress in Amsterdam by Michel Laviolette, M.D., Professor of Medicine, Institut universitaire de cardiologie et de pneumologie at Université Laval in Québec City, Canada.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/bostonscientific/52128/
Royal Philips Electronics (NYSE: PHG, AEX: PHI) today introduced the HomeLox portable liquid oxygen system. The innovative system enables oxygen users to generate and store the liquid form of oxygen in the home setting. The HomeLox system offers users the long-lasting and lightweight characteristics of traditional liquid systems, while freeing them from difficulties of filling and dependence on deliveries associated with conventional systems.
Home oxygen is a critical, life-sustaining medical treatment prescribed to nearly 1.5 million Medicare patients annually who suffer from respiratory illnesses such as chronic obstructive pulmonary disease (COPD).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/philips/45648/